
|Slideshows|October 20, 2022
Latest Research: COVID-19 Vaccines
Author(s)Lauren Biscaldi, MS
A selection of the latest COVID-19 vaccine research out of IDWeek 2022.
Advertisement
COVID-19 remained top of mind at IDWeek 2022, with dozens of posters, oral abstracts, and symposia presenting new research on the topic. Click through the slideshow to read a selection of the latest research on COVID-19 vaccines and follow along with Drug Topics® continuing coverage of IDWeek 2022.
References
- Niu J, Sareli C, Mayer D, Visbal A, Sareli AE. A population-based propensity score-matched study of COVID-19 vaccination on clinical outcomes in hospitalized adult patients with COVID-19. Presented at: IDWeek 2022; October 19-23, 2022; Washington, D.C. Poster 1928.
- Burns JE, Altamirano J, Salinas J, et al. Effect of vaccination on household transmission of SARS-CoV-2. Presented at: Presented at: IDWeek 2022; October 19-23, 2022; Washington, D.C. Poster 1943.
- Lytras T, Mellou K, Gkolfinopoulou K, et al. Effectiveness of COVID-19 vaccines against severe disease and death and its durability over time against the Omicron variant. Presented at: IDWeek 2022; October 19-23, 2022; Washington, D.C. Poster 1944.
- Hoskins S, Restrepo MI, Cadena J. Effects of COVID-19 vaccines on outcomes among hospitalized COVID-19 patients. Presented at: IDWeek 2022; October 19-23, 2022; Washington, D.C. Poster 1945.
- Watanabe A, Yasuhara J, Iwagami M, et al. Peripartum outcomes associated with COVID-19 vaccination during pregnancy: A systematic review and meta-analysis. Presented at: IDWeek 2022; October 19-23, 2022; Washington, D.C. Poster 1963.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Eli Lilly, Walmart Announce Expansion of Direct-to Consumer Access for Tirzepatide
2
White House Announces Action to Increase Competition, Decrease Cost of Biosimilar Development
3
FDA Approves Mirikizumab as Once Monthly Injection for Moderately to Severely Active Ulcerative Colitis
4
American Pharmacists Month: Clinical Service Expansion Benefits Patient Outcomes, Pharmacist Profession
5


























































































































































